Crossmark

Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study

Crossref DOI link: https://doi.org/10.1007/s00213-026-07104-w

Published Online: 2026-06-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kirsch, Julian

Poppe, Christopher

Beck, Anne

Brabeck, Anna

Gutwinski, Stefan

Lütt, Alva

Rosenthal, Annika

Tsamitros, Nikolaos

Repantis, Dimitris
Funding

Funding for this research was provided by:

Charité - Universitätsmedizin Berlin
License Information

Text and Data Mining valid from 2026-06-10

Version of Record valid from 2026-06-10
More Information

Article History

Received: 6 January 2026

Accepted: 4 June 2026

First Online: 10 June 2026

Declarations

:

: For ethical approval and informed consent within the clinical trials see the registrations (NCT06333457 and NCT06308484). The qualitative study was approved by the ethics commission of Charité Berlin (EA4/176/24), and all procedures adhered to the Declaration of Helsinki. All participants provided written informed consent, which outlined the voluntary and uncompensated nature of their participation, their right to withdraw at any time, and guarantees of confidentiality.

: Julian Kirsch, Christopher Poppe, Anne Beck, Anna Brabeck, Stefan Gutwinski, Alva Lütt, Annika Rosenthal and Nikolaos Tsamitros have no conflicts of interest to disclose. The institution of Dimitris Repantis has received research support from MAPS Europe B.V., COMPASS Pathways plc., and Beckley Psytech ltd. DR is a founding member and honorary Board Chair of MAPS Deutschland, a Germany-based non-profit research and educational organization associated with MAPS.

: A part of this study was embedded within two clinical trials. ID: NCT06333457 and NCT06308484.

Document is current

Any future updates will be listed below